Allos Therapeutics to provide FOLOTYN trial results in ESMO Congress Allos Therapeutics.

Presentation details are as follows: Presentation Date/Time: Mon, 11 October, 13:15 – 14:30 CEST Poster Name: ‘Randomized Phase 2b Research of Pralatrexate vs Erlotinib in Individuals with Stage IIIB/IV Non-small Cell Lung Tumor after Failure of Prior Platinum-Centered Therapy’ First Author: K. Kelly, University of Kansas, Kansas City/US Abstract Quantity: LBA17 Location: Chest tumors II, Gold Hall.. Allos Therapeutics to provide FOLOTYN trial results in ESMO Congress Allos Therapeutics, Inc. ‘We believe they are important results for the cancer community – producing data on the efficacy and security profile for FOLOTYN in this treatment establishing where there remains a higher unmet need – and so are delighted that the ESMO Congress has accepted these data as a late-breaking abstract to be highlighted in an oral display.The reference group comprised nonusers , and the estimates of relative risk had been adjusted for age, twelve months, length of schooling, educational level , and status regarding hypertension, heart disease, diabetes, and hyperlipidemia . Imputed ideals for lacking data on smoking position were calculated with the use of standard procedures of imputation,24 and sensitivity analyses that included imputation for smoking status were conducted .